Company intelligence / Profile preview

AazeinTx

Calgary, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

AazeinTx is developing a fast-acting oral compound, NEO6860, that targets a novel neural pathway (mediated by the TRPV1 receptor) to relieve bronchoconstriction in asthma, providing rapid relief without the need for inhalers. The approach is based on breakthrough research at the University of Calgary and has progressed beyond preclinical studies to clinical trials, with the company currently preparing for a Phase IIa trial.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

adMare BioInnovations (exclusive global licensing agreement for NEO6860)

Beyond the preview

Go deeper on AazeinTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AazeinTx.

Explore the full profile